We hope you'll enjoy learning from these experts!

All times are in ET

Register for the 27th Annual Meeting

Kevin Campbell, PhD, University of Iowa

Dr. Campbell is a professor, Roy J. Carver Biomedical Research Chair in Molecular Physiology and Biophysics, and director of the Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center at the University of Iowa's Carver College of Medicine. He's also an investigator at the Howard Hughes Medical Institute. Research in Dr. Campbell's lab is focused on the mechanism of muscular dystrophies and development of therapeutic strategies to treat muscular dystrophy. His studies on dystroglycan have since led to significant insights into its basic function as an extracellular matrix receptor in skeletal muscle, its role in the maintenance of muscle-cell membrane integrity, and its role in the molecular pathogenesis of glycosylation deficient muscular dystrophy.

Charles Murry, MD, PhD, University of Washington Medicine

Dr. Murry is a professor as well as the William and Marilyn Conner Chair and director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington School of Medicine. He is a cardiovascular pathologist whose clinical interests span ischemic heart disease, cardiac transplantation, atherosclerosis, heart failure, cardiomyopathy, valvular disease, and non-atherosclerotic vascular disease. The Murry lab is a multidisciplinary group, spanning molecular regulation of stem cell differentiation, animal models of disease, and studies of human tissue. The lab has a longstanding interest in the biology of myocardial infarction (heart attack), with the goal of harnessing stem cells to promote regeneration of heart muscle and the coronary circulation. (Photo courtesy of the University of Washington)

Drs. Campbell and Murry will speak during the Presidential Symposium on Wednesday, May 8, 10:15 a.m. - 12 p.m.

Beverly Davidson, PhD, Children's Hospital of Philadelphia

Dr. Davidson is director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and the Arthur V. Meigs Chair in Pediatrics at Children's Hospital of Philadelphia. She's also a professor at the Perelman School of Medicine at the University of Pennsylvania and chief scientific strategy officer at the Children's Hospital of Philadelphia Research Institute. Dr. Davidson's lab is focused on genetic diseases that affect the brain, studying the mechanisms by which mutant gene products contribute to disease, and why certain brain regions are more susceptible. The team employs advanced molecular methods, sequencing, and imaging modalities in animal models. Dr. Davidson's lab is also engaged in the development of next generation therapeutics for inherited disorders, including the engineering of novel gene therapy vector capsids and cargo to approach tissue and cell type specific treatments.

Philip Gregory, DPhil, 2seventy bio

Dr. Gregory is the chief scientific officer at 2seventy bio. Prior to his current position, Dr. Gregory served in the same role at Bluebird Bio for six years and in multiple leadership positions at Sangamo BioSciences for almost 15 years. At Bluebird, he was one of the early investigators in the now exploding field of genome editing, and a substantial fraction of his research interests lie in the basic science, discovery, development, and translation of genome editing technologies for clinical applications. At Sangamo, Dr. Gregory drove research that led to the company's leadership in developing therapeutics using both zinc finger nuclease editing technology and ZFP-based engineered transcription factors. His passion for genome editing is to solve the myriad of challenges, including the efficiency and precision of the genome engineering outcome, for both ex vivo and in vivo applications of this powerful technology.

Drs. Davidson and Gregory will speak during the George Stamatoyannopoulos Symposium on Thursday, May 9, 10:15 a.m. - 12 p.m.

Register for the 27th Annual Meeting